ＰＳＫによる頭けい部悪性しゅようの治療成績

DOI Web Site

書誌事項

タイトル別名
  • A Clinical Study of PSK in Head and Neck Malignancy
  • PSK ニヨル トウケイブ アクセイ シュヨウ ノ チリョウ セイセキ

この論文をさがす

抄録

A clinical study of PSK (protein-bound polysaccaride) was carried out in 169 patients with head and neck malignancy and the following results were obtained.<br>1. PSK was administered to 82 (48.5%) out of the 169 cases basically treated by irradiation and/or surgery.<br>2. The one year survival rate (95.0%) of patients with laryngeal cancer treated by irradiation combined with chemotherapy with or without PSK was better than that (45.2%) of patients solely treated by irradiation. On the other hand, the effect of antitumor agents including PSK on the malignant tumor of nose and paranasal sinuses was not evident.<br>3. The 18-month survival rate (63.6%) of patients with pharyngeal cancer who received supplementary administration of 5-FU or FT-207 combined with PSK was higher than that (16.7%) of patients treated only with 5-FU or FT-207. A similar effect of PSK was observed in the analysis of patients with oral cancer; the 18-month survival rate of patients supplementally treated with 5-FU or FT-207 combined with PSK was 66.7% and that of patients who received no PSK was 16.7%.<br>4. No side-effects of PSK were found in this series.<br>The present study indicates that various antineoplastic therapies for treatment of head and neck malignancy may produce good results when PSK is continuously administered concomitantly.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ